{"filings":[{"id":2410116,"accession_number":"0001178913-26-004223","cik":2022416,"company_name":"Silexion Therapeutics Corp","ticker":"SLXN","form_type":"8-K","filed_at":"2026-08-21T20:21:14+00:00","items":["3.01"],"status":"ready","headline":"Silexion receives Nasdaq delisting notice for equity shortfall; plans appeal","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq delisting notice received Aug 18, 2026 for failure to meet $2.5M shareholders' equity requirement (Rule 5550(b)(1)).","Shareholders' equity as of June 30, 2026 was only $44,000, far below required minimum.","Company intends to appeal by Aug 25, 2026; under Mandatory Hearings Panel Monitor limiting compliance extensions.","If appeal fails, ordinary shares and warrants (SLXN, SLXNW) will be suspended and delisted via Form 25-NSE."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1744277.6056370838,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":"2026-08-21","daily_digest_url":"/daily/2026-08-21","daily_digest_rank":1},{"id":2254236,"accession_number":"0001178913-26-004136","cik":2022416,"company_name":"Silexion Therapeutics Corp","ticker":"SLXN","form_type":"8-K","filed_at":"2026-08-14T13:00:38+00:00","items":["2.02","9.01"],"status":"ready","headline":"Silexion Q2 net loss widens to $3.6M; Phase 2/3 trial initiated","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net loss $3.6M vs $2.5M YoY; R&D up 120% to $2.2M on trial prep.","Six-month net loss $6.3M vs $4.2M; cash $2.2M at June 30, down from $6.0M.","Closed Aug 13 public offering gross $2.5M, net $2.1M; equity est. $3.2M, restoring Nasdaq compliance.","Phase 2/3 SIL204 trial initiated July 29 at Tel Aviv Sourasky; approvals from Germany BfArM and Israel.","1-for-10 reverse split May 28, 2026; preclinical data supports immune-sensitization across 4 KRAS mutations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1744277.6056370838,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2246237,"accession_number":"0001178913-26-004128","cik":2022416,"company_name":"Silexion Therapeutics Corp","ticker":"SLXN","form_type":"8-K","filed_at":"2026-08-13T21:06:26+00:00","items":["8.01","9.01"],"status":"ready","headline":"Silexion restates FY2025 financials for 1-for-10 reverse split; auditor flags going concern","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FY2025 net loss $11.9M vs $16.5M in 2024; operating loss $11.6M vs $12.6M.","Cash and equivalents $5.99M at Dec 31, 2025, up from $1.19M; total assets $7.2M.","Auditor expresses substantial doubt about ability to continue as going concern due to recurring losses.","1-for-10 reverse split effective May 28, 2026; all share and per-share data retroactively adjusted.","R&D spend rose to $7.1M from $5.8M; G&A fell to $4.5M from $6.8M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1744277.6056370838,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2243839,"accession_number":"0001178913-26-004122","cik":2022416,"company_name":"Silexion Therapeutics Corp","ticker":"SLXN","form_type":"8-K","filed_at":"2026-08-13T20:02:40+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Silexion closes $2.5M public offering; converts $750K debt to equity","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offered 2,028,619 shares, 1,817,542 pre-funded warrants, 3,846,161 Series E warrants at $0.65/unit; gross proceeds ~$2.5M.","Net proceeds ~$2.1M; intended for SIL204 clinical trial and general corporate purposes.","Converted $750,001 of sponsor note into 1,153,848 ordinary shares at $0.65/share; note balance now $206,462.","Issued 823,770 shares from pre-funded warrant exercises; adjusted shareholders' equity ~$3.2M as of June 30, 2026.","H.C. Wainwright sole placement agent; fees 7% cash, 1% management, plus 269,231 placement agent warrants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1744277.6056370838,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2143836,"accession_number":"0001178913-26-003966","cik":2022416,"company_name":"Silexion Therapeutics Corp","ticker":"SLXN","form_type":"8-K","filed_at":"2026-08-10T10:16:08+00:00","items":["7.01","9.01"],"status":"ready","headline":"Silexion starts SIL204 Phase 2/3 in pancreatic cancer; FDA pre-IND expected Q1 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2/3 safety run-in for SIL204 in LAPC initiated July 2026; approved by Israel MoH and Germany BfArM.","Early human data expected Q4 2026; IND application and US/EU expansion planned Q1 2027.","SIL204 targets >74% of KRAS mutations in PDAC; sub-nanomolar IC50 across G12D/V/C/R and others.","Preclinical data show tumor growth inhibition, synergy with FOLFIRI, and 11-fold safety margins.","Toxicology package for marketing approval planned H2 2026; collaboration with Catalent and Axolabs for GMP supply."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1744277.6056370838,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2051680,"accession_number":"0001178913-26-003796","cik":2022416,"company_name":"Silexion Therapeutics Corp","ticker":"SLXN","form_type":"8-K","filed_at":"2026-08-04T20:10:48+00:00","items":["7.01","9.01"],"status":"ready","headline":"Silexion: SIL204 shows multi-mechanism immune sensitization in KRAS-driven cancers","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SIL204 treatment produced statistically significant upregulation of FAS (death receptor) and downregulation of HLA-G (immune checkpoint) in human KRAS-mutant pancreatic and NSCLC cell lines.","Combined with prior MHC-I upregulation, data supports coordinated immune-sensitization across three key immune pathways.","Findings observed across four distinct KRAS mutations (G12D, G12V, G12C, G12R) in pancreatic and NSCLC models.","Company advancing SIL204 into Phase 2/3; first clinical trial site initiated at Tel Aviv Sourasky Medical Center in July 2026.","Management believes data supports combining SIL204 with anti-PD-(L)1 checkpoint inhibitors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1744277.6056370838,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2008316,"accession_number":"0001178913-26-003761","cik":2022416,"company_name":"Silexion Therapeutics Corp","ticker":"SLXN","form_type":"8-K","filed_at":"2026-08-03T13:28:21+00:00","items":["8.01"],"status":"ready","headline":"Silexion Therapeutics appoints Avner Lushi to audit committee after Peled resignation","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Professor Amnon Peled resigned from board and audit committee effective Aug 1, 2026 for personal reasons, no disagreement.","Avner Lushi, existing independent board member, appointed to audit committee effective Aug 1, 2026.","Audit committee now has three independent members: Dror J. Abramov (Chair), Ruth Alon, and Avner Lushi, restoring Nasdaq compliance.","Lushi is Managing Partner and CEO of Guangzhou Sino-Israel Bio-industry Investment Fund (GIBF)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1744277.6056370838,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1995076,"accession_number":"0001178913-26-003742","cik":2022416,"company_name":"Silexion Therapeutics Corp","ticker":"SLXN","form_type":"8-K","filed_at":"2026-07-31T20:06:33+00:00","items":["5.02"],"status":"ready","headline":"Director Amnon Peled resigns from Silexion Therapeutics board effective August 1, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Professor Amnon Peled resigned from the Board of Directors for personal reasons, effective August 1, 2026.","Resignation did not result from any disagreement with the Company on operations, policies, or practices.","No replacement director has been announced as of the filing date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1744277.6056370838,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1940564,"accession_number":"0001178913-26-003690","cik":2022416,"company_name":"Silexion Therapeutics Corp","ticker":"SLXN","form_type":"8-K","filed_at":"2026-07-29T20:05:46+00:00","items":["7.01","9.01"],"status":"ready","headline":"Silexion initiates Phase 2/3 trial of SIL204 in pancreatic cancer at Tel Aviv Sourasky Medical Center","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First clinical site activated at Tel Aviv Sourasky Medical Center; patient screening to begin in coming weeks.","Phase 2/3 trial of SIL204 (siRNA) for locally advanced pancreatic cancer; follows regulatory approvals from Israeli MoH and German BfArM.","Trial includes safety run-in (~18 patients) then randomized cohort (~166 patients); dual-route administration (intratumoral + systemic).","Additional Israeli and German sites expected to join in coming months; first patient dosing anticipated as next milestone.","SIL204 targets broad range of KRAS mutations; KRAS mutations present in ~90% of pancreatic cancers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1744277.6056370838,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1775237,"accession_number":"0001178913-26-003551","cik":2022416,"company_name":"Silexion Therapeutics Corp","ticker":"SLXN","form_type":"8-K","filed_at":"2026-07-21T20:05:53+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Silexion shareholders approve 10M share authorized increase and warrant exercisability","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Meeting reconvened July 20, 2026 after July 13 adjournment due to lack of quorum.","Proposal 1 (warrant exercisability) approved with 93.3% in favor (214,091 votes for, 15,293 against).","Proposal 2 (authorized share increase) approved with 89.8% in favor (205,551 for, 23,382 against).","Authorized shares increased from 5,900,000 to 15,900,000 ordinary shares (par value $0.135).","Memorandum Amendment filed with Cayman Islands Registrar on July 21, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1744277.6056370838,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":731156,"accession_number":"0001178913-26-002988","cik":2022416,"company_name":"Silexion Therapeutics Corp","ticker":"SLXN","form_type":"8-K","filed_at":"2026-05-29T11:00:25+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"Silexion Therapeutics completes 1-for-10 reverse share split; warrants adjusted","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["1-for-10 reverse share split effective after close May 28; shares trade on split-adjusted basis May 29 under ticker SLXN.","Authorized shares reduced to 5.9M; par value increased to $0.135 per share.","Each warrant now exercisable for 1/10 share at $15,525.00 per whole share (was $1,552.50).","Shareholders approved reverse split at reconvened EGM on May 5, 2026.","Split intended to maintain compliance with Nasdaq minimum bid price requirement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1744277.6056370838,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":650156,"accession_number":"0001178913-26-002900","cik":2022416,"company_name":"Silexion Therapeutics Corp","ticker":"SLXN","form_type":"8-K","filed_at":"2026-05-26T12:48:49+00:00","items":["8.01","9.01"],"status":"ready","headline":"Silexion Therapeutics announces 1-for-10 reverse share split to maintain Nasdaq listing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse share split at 1:10 ratio; effective after market close May 28, 2026; split-adjusted trading begins May 29, 2026.","Ticker remains SLXN; new CUSIP assigned; par value increases from $0.0135 to $0.135 per share.","No fractional shares issued; DTC participants' fractional shares rounded up to nearest whole share.","Split intended to maintain Nasdaq minimum bid price compliance (Rule 5550(a)(2)) and support equity financings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1744277.6056370838,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":482796,"accession_number":"0001178913-26-002761","cik":2022416,"company_name":"Silexion Therapeutics Corp","ticker":"SLXN","form_type":"8-K","filed_at":"2026-05-18T12:33:17+00:00","items":["2.02","9.01"],"status":"ready","headline":"Silexion Therapeutics Q1 net loss $2.7M; cash $2.4M; Phase 2/3 trial on track for Q2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $2.7M for Q1 2026 vs $1.7M in Q1 2025; R&D expenses rose 133% to $1.4M driven by trial preparation.","Cash and equivalents $2.4M at Mar 31, 2026, down from $6.0M at Dec 31, 2025; post-quarter capital raises of $1.0M from warrant inducement.","Israeli Ministry of Health approved Phase 2/3 trial of SIL204 for locally advanced pancreatic cancer; CTA submitted to Germany.","Phase 2/3 trial initiation remains on track for Q2 2026 with safety run-in of ~18 patients, then randomized cohort of ~166.","Company believes post-quarter equity transactions restored Nasdaq compliance with $2.5M minimum shareholders' equity requirement."],"consensus_eps_estimate":-1.3158,"consensus_eps_actual":0.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1744277.6056370838,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":471517,"accession_number":"0001178913-26-002739","cik":2022416,"company_name":"Silexion Therapeutics Corp","ticker":"SLXN","form_type":"8-K","filed_at":"2026-05-15T20:27:48+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Silexion Therapeutics enters inducement agreement for exercise of ~2M warrants at $0.50, raising ~$1M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Holders of 1,995,092 existing warrants (Series A/B at $4.00, Prior Inducement at $11.32) agree to exercise at reduced price of $0.50 per share.","Gross proceeds of approximately $1.0 million expected from the warrant exercise, with H.C. Wainwright as placement agent earning 7% cash fee.","Company will issue new Series C (2,045,000) and Series D (1,945,184) warrants exercisable at $0.50, totaling 3,990,184 new warrant shares.","Closing expected on or about May 18, 2026, with net proceeds used for general corporate purposes.","Placement agent also receives warrants to purchase up to 139,656 ordinary shares at $0.625 per share."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1744277.6056370838,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":442758,"accession_number":"0001178913-26-002705","cik":2022416,"company_name":"Silexion Therapeutics Corp","ticker":"SLXN","form_type":"8-K","filed_at":"2026-05-14T20:11:39+00:00","items":["7.01","9.01"],"status":"ready","headline":"Silexion reports positive preclinical SIL204 data showing increased MHC-I in KRAS-mutated pancreatic cancer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SIL204 significantly increased MHC-I (HLA-ABC) surface expression in human KRAS G12R pancreatic cancer cells at 60 nM (p<0.05).","Increased MHC-I may enhance T cell recognition, supporting potential combination with anti-PD-1 therapies like Keytruda.","CEO Ilan Hadar said SIL204 may influence immune evasion pathways in addition to direct anti-tumor activity.","Pancreatic cancer is immunologically resistant; MHC-I loss is a key immune evasion mechanism in KRAS-driven tumors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1744277.6056370838,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":50721,"accession_number":"0001178913-26-002624","cik":2022416,"company_name":"Silexion Therapeutics Corp","ticker":"SLXN","form_type":"8-K","filed_at":"2026-05-13T12:41:07+00:00","items":["7.01","9.01"],"status":"ready","headline":"Silexion begins GMP manufacturing of SIL204 with Catalent; Phase 2/3 trial approved at Israeli site","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Initiated GMP clinical batch manufacturing of SIL204 with Catalent at its Limoges, France center of excellence.","Tel Aviv Sourasky Medical Center Helsinki Ethics Committee approved planned Phase 2/3 trial of SIL204 in LAPC.","SIL204 is a next-generation siRNA therapy targeting mutated KRAS, most common oncogenic driver in cancers.","Phase 2/3 trial to evaluate SIL204 with standard-of-care chemo using dual-route (intratumoral + systemic) administration.","Israeli Ministry of Health already approved the trial; CTA submitted to Germany; preparing for first patient dosing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1744277.6056370838,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97260,"accession_number":"0001178913-26-002393","cik":2022416,"company_name":"Silexion Therapeutics Corp","ticker":"SLXN","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Silexion shareholders approve 50M share increase, expanded equity plan, and 1-for-10 reverse split","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized shares increased from 9M to 59M via Memorandum Amendment effective May 5, 2026.","Equity incentive plan evergreen provision raised from 5% of outstanding to pool of 10% fully diluted shares annually.","Reverse stock split at 1-for-10 approved; can be reduced to maintain Nasdaq minimum public float.","All three proposals passed with ~61% of votes in favor at reconvened meeting with 40.2% quorum."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1744277.6056370838,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97259,"accession_number":"0001178913-26-002267","cik":2022416,"company_name":"Silexion Therapeutics Corp","ticker":"SLXN","form_type":"8-K","filed_at":"2026-04-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Silexion submits Phase 2/3 trial application to Germany's BfArM for SIL204 in KRAS-driven pancreatic cancer","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Silexion submitted CTA to Germany’s BfArM for Phase 2/3 trial of SIL204 in KRAS-driven locally advanced pancreatic cancer.","Germany will serve as EU Reference Member State; trial initiation remains on track for Q2 2026.","Submission supported by completed two-species toxicology studies confirming no systemic organ toxicity.","Planned trial will evaluate SIL204 in combination with standard chemotherapy using dual-route administration.","Pancreatic cancer has <13% five-year survival; KRAS mutations present in about 90% of cases."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1744277.6056370838,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111888,"accession_number":"0001178913-26-001722","cik":2022416,"company_name":"Silexion Therapeutics Corp","ticker":"SLXN","form_type":"8-K","filed_at":"2026-03-25T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Silexion Therapeutics removes director Ilan Levin effective March 25, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ilan Levin removed from Board on March 25, 2026 by unanimous vote of other directors.","Removal effective immediately; no reason disclosed in filing.","No replacement director named or resignation reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1744277.6056370838,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111887,"accession_number":"0001178913-26-001615","cik":2022416,"company_name":"Silexion Therapeutics Corp","ticker":"SLXN","form_type":"8-K","filed_at":"2026-03-24T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Silexion gets Israeli MoH approval for Phase 2/3 trial of SIL204 in pancreatic cancer","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["SIL204 is a next-generation RNAi therapy targeting multiple KRAS mutations in pancreatic cancer.","Approval follows positive preclinical anti-tumor data and completed toxicology studies.","Human trials expected to begin in Q2 2026; also planning German application in current quarter.","Company plans to pursue additional KRAS-driven indications including colorectal and lung cancers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1744277.6056370838,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111886,"accession_number":"0001178913-26-001597","cik":2022416,"company_name":"Silexion Therapeutics Corp","ticker":"SLXN","form_type":"8-K","filed_at":"2026-03-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Silexion Therapeutics shareholders vote down share capital increase and equity plan expansion","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["At reconvened EGM on March 23, 2026, quorum met with 1,216,369 shares (36.6% of outstanding).","Proposal to increase authorized shares from 9M to 59M failed: 38.2% for, 61.8% against.","Proposal to expand evergreen provision of 2024 equity plan to 10% fully diluted failed: 40.7% for, 59.3% against.","Neither proposal received the simple majority required for approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.15,"market_cap_usd":1744277.6056370838,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111885,"accession_number":"0001178913-26-000289","cik":2022416,"company_name":"Silexion Therapeutics Corp","ticker":"SLXN","form_type":"8-K","filed_at":"2026-02-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Silexion Therapeutics files 8-K disclosing corporate presentation for non-deal roadshow","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed Form 8-K on February 3, 2026, with Items 7.01 and 9.01.","Prepared a corporate presentation for use in investor meetings as part of a non-deal roadshow.","Presentation furnished as Exhibit 99.1 and incorporated by reference.","CEO Ilan Hadar signed the report on behalf of Silexion Therapeutics Corp.","Presentation titled 'Silencing Oncogenes at the Level of Gene Expression' for Nasdaq: SLXN."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1744277.6056370838,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111884,"accession_number":"0001178913-26-000067","cik":2022416,"company_name":"Silexion Therapeutics Corp","ticker":"SLXN","form_type":"8-K","filed_at":"2026-01-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Silexion CEO letter details 2025 progress; Phase 2/3 trial in LAPC set for H1 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SIL204 showed >90% inhibition in human cancer cell lines across 8 KRAS mutations and 5 tumor types.","Positive regulatory feedback from Germany's BfArM on Phase 2/3 design; toxicology studies completed.","Phase 2/3 LAPC trial initiation planned H1 2026; US IND expected H2 2026.","Company raised over $18M in 2025 and regained Nasdaq compliance; addressable market >$30B."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1744277.6056370838,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128513,"accession_number":"0001178913-25-004067","cik":2022416,"company_name":"Silexion Therapeutics Corp","ticker":"SLXN","form_type":"8-K","filed_at":"2025-12-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Silexion submits Phase 2/3 trial application for SIL204 in locally advanced pancreatic cancer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Submitted Phase 2/3 clinical trial application in Israel for SIL204, a siRNA therapy for locally advanced pancreatic cancer (LAPC).","Phase 2/3 trial initiation planned for Q2 2026; follow-on regulatory filings in Germany/EU in Q1 2026.","Preclinical data demonstrated up to 99.7% cancer cell inhibition across multiple KRAS mutations.","Two completed species toxicology studies confirmed no systemic organ toxicity; positive German regulatory feedback received.","Collaborating with Sheba Medical Center (top-10 global hospital) for Israeli trial; U.S. expansion after safety run-in."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1744277.6056370838,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128512,"accession_number":"0001178913-25-003981","cik":2022416,"company_name":"Silexion Therapeutics Corp","ticker":"SLXN","form_type":"8-K","filed_at":"2025-12-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Silexion receives positive BfArM feedback on Phase 2/3 trial design for SIL204 in pancreatic cancer","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["BfArM written Scientific Advice supports proposed Phase 2/3 study design, dosing, patient population, and CMC.","Phase 2/3 trial initiation for SIL204 planned for Q2 2026, pending regulatory clearance.","Regulatory submissions expected in Israel by end of Q4 2025 and in Germany during Q1 2026.","SIL204 targets KRAS-driven locally advanced pancreatic cancer; momentum builds toward clinical launch."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1744277.6056370838,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128511,"accession_number":"0001178913-25-003949","cik":2022416,"company_name":"Silexion Therapeutics Corp","ticker":"SLXN","form_type":"8-K","filed_at":"2025-11-25T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Silexion completes toxicology studies for SIL204; Phase 2/3 trial on track for Q2 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Two-species toxicology studies for SIL204 confirm no systemic organ toxicity, clearing path to regulatory filings.","Regulatory submissions planned to Israel Ministry of Health and Germany's BfArM ahead of Phase 2/3 trial.","Phase 2/3 clinical trial in locally advanced pancreatic cancer (LAPC) expected to initiate in Q2 2026.","CRO partner for the trial has been secured; SIL204 targets mutant KRAS oncogenes via siRNA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1744277.6056370838,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128510,"accession_number":"0001178913-25-003756","cik":2022416,"company_name":"Silexion Therapeutics Corp","ticker":"SLXN","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Silexion Q3 net loss narrows to $3.3M; cash $9.2M; Phase 2/3 trial on track for H1 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $3.3M ($2.88/share) vs $11.9M ($274.25) a year ago, aided by lower share-based compensation.","Cash and equivalents $9.2M as of Sep 30, up from $1.2M at Dec 2024, after raising ~$9.5M in Q3.","R&D spend $2.2M (-31% YoY); G&A $1.1M (-77% YoY); shareholders' equity improved to $7.0M.","Phase 2/3 trial of SIL204 in KRAS-driven cancers on track for H1 2026; regulatory submissions planned for Q4 2025/Q1 2026.","New preclinical data shows SIL204 efficacy across five cancer types, including first gastric cancer evidence."],"consensus_eps_estimate":null,"consensus_eps_actual":10.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1744277.6056370838,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145322,"accession_number":"0001178913-25-003444","cik":2022416,"company_name":"Silexion Therapeutics Corp","ticker":"SLXN","form_type":"8-K","filed_at":"2025-09-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Silexion reports SIL204 shows up to 99.7% inhibition across 11 human cell lines, first gastric cancer data","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SIL204 achieved 83.5% to 99.7% inhibition at nanomolar concentrations (IC50 23.4–85.3 nM) in 11 lines from 5 cancer types.","Highest activity: 99.7% inhibition in NCIH2009 lung cells (G12A mutation); first gastric cancer data showed 89.2% inhibition (G12D).","Pancreatic G12R (17% of cases) showed 91.5% inhibition (IC50 31.5 nM) in KP2 cells; expanded colorectal validation in HCT 116 (G13D).","SIL204 now confirmed active against G12D, G12V, G12R, G12C, G13C, G12A, Q61H, and G13D mutations.","Phase 2/3 trial planned H1 2026; regulatory submissions to Israel MoH in Q4 2025 and EU in Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1744277.6056370838,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145321,"accession_number":"0001178913-25-003385","cik":2022416,"company_name":"Silexion Therapeutics Corp","ticker":"SLXN","form_type":"8-K","filed_at":"2025-09-26T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Silexion Therapeutics enters ATM equity facility for up to $13.17M via H.C. Wainwright","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["At-the-market offering agreement with H.C. Wainwright to sell up to $13.17M of ordinary shares.","Wainwright to receive 3% commission on gross proceeds; sales may occur via Nasdaq Capital Market.","Offering terminates upon sale of all shares or earlier termination by either party.","Company not obligated to sell any shares; sales subject to effectiveness of registration statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1744277.6056370838,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145320,"accession_number":"0001178913-25-003374","cik":2022416,"company_name":"Silexion Therapeutics Corp","ticker":"SLXN","form_type":"8-K","filed_at":"2025-09-25T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Silexion Therapeutics regains Nasdaq compliance; subject to one-year monitor","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq compliance letter on Sep 23, 2025 for equity (≥$2.5M) and minimum bid price ($1.00) requirements.","Financing transactions increased shareholders' equity by $10.3M to ~$9.41M as of Sep 15, 2025.","1-for-15 reverse stock split on Jul 29, 2025 brought bid price above $1.00.","Subject to mandatory panel monitor until Sep 23, 2026; any future non-compliance may lead to immediate delisting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1744277.6056370838,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145319,"accession_number":"0001178913-25-003329","cik":2022416,"company_name":"Silexion Therapeutics Corp","ticker":"SLXN","form_type":"8-K","filed_at":"2025-09-15T23:59:59+00:00","items":["3.02","8.01","9.01"],"status":"ready","headline":"Silexion regains Nasdaq compliance with $9.4M equity after capital raise","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Issued 450,000 shares to sponsor upon converting $1.8M of convertible note at $4.00/share; remaining $1.6M outstanding.","Shareholders' equity rose to ~$9.4M from -$0.7M at July 31, 2025, after four transactions.","Company affirms compliance with Nasdaq Capital Market equity requirement of $2.5M and expects long-term compliance.","Gross proceeds from September 2025 public offering: ~$6.0M from sale of shares/pre-funded warrants and warrants.","Warrant exercise inducement in August 2025 generated ~$1.8M gross proceeds."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1744277.6056370838,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145318,"accession_number":"0001178913-25-003309","cik":2022416,"company_name":"Silexion Therapeutics Corp","ticker":"SLXN","form_type":"8-K","filed_at":"2025-09-12T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Silexion Therapeutics prices $6.0M public offering of shares and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raised $6.0M gross ($5.2M net) from sale of 1.5M share equivalents and warrants at $4.00/unit.","Offering includes Series A (5-year) and Series B (12-month) warrants, each exercisable at $4.00/share.","Placement agent H.C. Wainwright receives 7% cash fee plus 105,000 placement agent warrants at $5.00.","Net proceeds to fund pre-clinical studies and general corporate purposes.","Offering closed on Sept 12, 2025; securities registered under Form S-1 effective Sept 11."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1744277.6056370838,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145317,"accession_number":"0001178913-25-003292","cik":2022416,"company_name":"Silexion Therapeutics Corp","ticker":"SLXN","form_type":"8-K","filed_at":"2025-09-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Silexion reports preclinical data showing SIL204 reaches metastatic sites in pancreatic cancer model","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Subcutaneous SIL204 (5 mg/mouse) distributed to liver, peritoneum, lung in Panc-1 KRAS G12D metastatic model.","Tumor burden reduced significantly (p<0.01) in peritoneum, lung, intestine; liver showed measurable reduction.","Data supports dual-route strategy: intratumoral for primary tumor, systemic for metastases.","Phase 2/3 trial on track for H1 2026; regulatory submissions planned Q4 2025 and Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1744277.6056370838,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145316,"accession_number":"0001178913-25-003248","cik":2022416,"company_name":"Silexion Therapeutics Corp","ticker":"SLXN","form_type":"8-K","filed_at":"2025-09-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Silexion selects CRO AMS for SIL204 Phase 2/3 trials; H1 2026 start expected","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CRO AMS has over 28 years of drug development experience and Phase 3 oncology trial expertise.","Regulatory submissions planned for Q4 2025 (Israel) and Q1 2026 (EU).","Phase 2/3 clinical trials for SIL204 expected to commence in first half of 2026.","SIL204 previously showed up to 97% inhibition in pancreatic cancer cells with KRAS Q61H mutations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1744277.6056370838,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145315,"accession_number":"0001178913-25-003205","cik":2022416,"company_name":"Silexion Therapeutics Corp","ticker":"SLXN","form_type":"8-K","filed_at":"2025-09-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Silexion posts updated corporate presentation for H.C. Wainwright conference","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Updated corporate presentation posted to company website on September 2, 2025.","Presentation to be presented on September 10, 2025 at H.C. Wainwright Global Investment Conference in New York.","No specific financial or clinical data disclosed in the 8-K filing excerpt."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1744277.6056370838,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145314,"accession_number":"0001178913-25-003005","cik":2022416,"company_name":"Silexion Therapeutics Corp","ticker":"SLXN","form_type":"8-K","filed_at":"2025-08-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Silexion Therapeutics 2024 net loss $16.5M, auditor flags going concern doubt","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss of $16.5M in 2024 vs $5.1M in 2023; operating expenses $12.6M.","Cash used in operations $8.4M; cash and equivalents $1.2M at Dec 31, 2024.","Auditor emphasizes substantial doubt about going concern due to recurring losses.","Total liabilities $6.9M exceed assets $2.9M; capital deficiency of $4.0M.","Financial statements retroactively adjusted for 1-for-15 reverse split effective July 28, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1744277.6056370838,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145313,"accession_number":"0001178913-25-002985","cik":2022416,"company_name":"Silexion Therapeutics Corp","ticker":"SLXN","form_type":"8-K","filed_at":"2025-08-19T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Silexion Therapeutics shareholders approve 6x increase in authorized shares to 9M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized capital raised from US$20,000 (1,481,482 shares) to US$121,500 (9,000,000 shares).","Vote results: 699,871 for (59.8%), 470,828 against (40.2%), 289,225 abstentions.","Meeting originally Aug 12, 2025, reconvened Aug 19 after no quorum; 16.8% of shares present constituted quorum under Articles.","Memorandum Amendment filed and effective in Cayman Islands on August 19, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1744277.6056370838,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145312,"accession_number":"0001178913-25-002784","cik":2022416,"company_name":"Silexion Therapeutics Corp","ticker":"SLXN","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Silexion Q2 net loss $2.5M, cash $3.5M; SIL204 shows up to 97% inhibition across KRAS cancers","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $2.5M for Q2 2025 vs $1.5M in Q2 2024; operating expenses up 64.3% to $2.3M.","Cash $3.5M at June 30, 2025 (up from $1.2M at Dec 31, 2024); warrant exercise raised ~$1.8M in July.","Preclinical: SIL204 achieved 94% inhibition in pancreatic, 90% in colorectal, up to 97% in KRAS Q61H pancreatic cancer cells.","Strategic collaboration with Catalent for formulation development; Phase 2/3 trial on track for H1 2026.","Nasdaq listing maintained after 1-for-15 reverse split and panel decision; pursuing $2.5M equity threshold."],"consensus_eps_estimate":null,"consensus_eps_actual":8.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.72,"calibrated_materiality_score":0.72,"market_cap_usd":1744277.6056370838,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145311,"accession_number":"0001178913-25-002570","cik":2022416,"company_name":"Silexion Therapeutics Corp","ticker":"SLXN","form_type":"8-K","filed_at":"2025-08-01T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Silexion exercises 152K warrants at $11.57 for ~$1.8M gross; issues new warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exercises 152,106 existing warrants at $11.57/share; gross proceeds ~$1.8M before fees.","Issues new warrants for up to 304,212 ordinary shares at $11.32/share; 24-month term from resale registration.","Closing expected August 1, 2025; shareholder meeting August 12 for authorized share increase.","H.C. Wainwright receives 7% cash fee, management fee, and warrants as placement agent.","Company to file resale registration statement within 30 days; 15-day lock-up and 1-year variable rate transaction ban."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1744277.6056370838,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145310,"accession_number":"0001178913-25-002559","cik":2022416,"company_name":"Silexion Therapeutics Corp","ticker":"SLXN","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Silexion reports new preclinical data: up to 97% cancer cell inhibition, first evidence against KRAS Q61H mutation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SIL204 achieved up to 97% inhibition in pancreatic cancer cells with KRAS Q61H mutation (previously untested).","Dose-dependent inhibition of up to 94% in pancreatic cancer cells with KRAS G12D mutation at nanomolar concentrations.","Nearly 90% inhibition in colorectal cancer cells with KRAS G12D mutation, extending efficacy beyond pancreatic cancer.","Data covers three major KRAS-driven cancers: pancreatic, colorectal, and lung; on track for Phase 2/3 trial in Q2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1744277.6056370838,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145309,"accession_number":"0001178913-25-002515","cik":2022416,"company_name":"Silexion Therapeutics Corp","ticker":"SLXN","form_type":"8-K","filed_at":"2025-07-29T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"Silexion Therapeutics effects 1-for-15 reverse stock split, adjusts warrant terms","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split effective after close July 28; trading on split-adjusted basis July 29 under same ticker SLXN.","Authorized shares unchanged at 1,481,482; par value increased from $0.0009 to $0.0135 per share.","Each warrant now exercisable for 1/15th of a share; exercise price adjusted to $1,552.50 per whole share.","No fractional shares will be issued; fractional interests rounded up to nearest whole share.","CUSIP for ordinary shares changed to G1281K 130; warrant CUSIP remains G1281K 114."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1744277.6056370838,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145308,"accession_number":"0001178913-25-002431","cik":2022416,"company_name":"Silexion Therapeutics Corp","ticker":"SLXN","form_type":"8-K","filed_at":"2025-07-21T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Silexion receives Nasdaq bid price deficiency notice; reverse split set for July 29","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On July 18, 2025, Nasdaq notified Silexion that its ordinary shares' closing bid price was below $1.00 for 30 consecutive days.","Bid price deficiency will be considered by Nasdaq hearings panel in continued listing decision.","Shareholder-approved 1-for-15 reverse split effective after market close July 28; trading begins split-adjusted July 29.","Company must also meet $2.5M minimum shareholders' equity by September 19, 2025 to maintain listing.","Current trading of shares (SLXN) and warrants (SLXNW) unaffected at this time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1744277.6056370838,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145307,"accession_number":"0001178913-25-002390","cik":2022416,"company_name":"Silexion Therapeutics Corp","ticker":"SLXN","form_type":"8-K","filed_at":"2025-07-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Silexion Therapeutics announces 1-for-15 reverse share split to maintain Nasdaq listing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split effective after market close July 28; split-adjusted trading starts July 29 under ticker SLXN.","Every 15 ordinary shares combined into 1; fractional shares rounded up to nearest whole share.","Par value increases from $0.0009 to $0.0135 per share; no action required from shareholders.","Split designed to regain compliance with Nasdaq minimum bid price rule (Listing Rule 5550(a)(2)).","CEO Ilan Hadar states split supports strategic growth initiatives and capital markets positioning."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1744277.6056370838,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145306,"accession_number":"0001178913-25-002378","cik":2022416,"company_name":"Silexion Therapeutics Corp","ticker":"SLXN","form_type":"8-K","filed_at":"2025-07-14T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Silexion shareholders approve 1-for-15 reverse split and board election","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse share split at 1-for-15 ratio approved with 59.6% of votes in favor.","Equity incentive plan shares increased by 1,271,859 to 1,428,268 total.","All seven director nominees elected; Ruth Alon (68.2%) and Ilan Levin (68.1%) received lowest support.","Ratification of Kesselman & Kesselman (PwC) as auditors approved with 98.3% in favor.","Meeting reconvened after July 7 adjournment due to lack of quorum; 12.1% of shares represented."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1744277.6056370838,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145305,"accession_number":"0001178913-25-002341","cik":2022416,"company_name":"Silexion Therapeutics Corp","ticker":"SLXN","form_type":"8-K","filed_at":"2025-07-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"SIL204 shows dose-dependent inhibition in KRAS G12D lung cancer cells in preclinical study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preclinical study demonstrates significant dose-dependent inhibition of human lung cancer cells with KRAS G12D mutation.","Company plans to release results of new study on previously untested KRAS mutation shortly; if positive, could support pan-KRAS potential.","SIL204's lipid-conjugated delivery system validated; overcoming a key barrier for siRNA in solid tumors.","Company continues to prepare for Phase 2/3 trial initiation in Q2 2026 for KRAS-driven solid tumors.","Builds on prior efficacy in pancreatic and colorectal cancer models; KRAS mutations occur in ~30% of lung cancers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1744277.6056370838,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145304,"accession_number":"0001178913-25-002333","cik":2022416,"company_name":"Silexion Therapeutics Corp","ticker":"SLXN","form_type":"8-K","filed_at":"2025-07-08T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Silexion Therapeutics wins Nasdaq hearing to stay listed; transfer to Capital Market with equity conditions","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq panel granted continued listing subject to achieving $2.5M shareholders' equity by Sept 19, 2025.","Shares and warrants transfer from Global Market to Nasdaq Capital Market effective July 8, 2025, under same symbols.","To cure potential bid price deficiency, company plans 1-for-15 reverse share split after shareholder meeting on July 14, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1744277.6056370838,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145303,"accession_number":"0001178913-25-002335","cik":2022416,"company_name":"Silexion Therapeutics Corp","ticker":"SLXN","form_type":"8-K/A","filed_at":"2025-07-08T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Silexion amends 8-K, delays Nasdaq transfer; reverse split expected in August to cure bid price deficiency","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq transfer to Capital Market not on July 8 as originally reported; now expected as soon as practicable.","Shareholder vote on 1-for-15 reverse split reconvenes July 14, 2025 at annual meeting.","After approval, 10-day Nasdaq notice period ends ~July 25; then 10 consecutive trading days above $1.00 needed.","Compliance with minimum bid price rule expected early to mid-August; no assurance of success."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1744277.6056370838,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163717,"accession_number":"0001178913-25-002045","cik":2022416,"company_name":"Silexion Therapeutics Corp","ticker":"SLXN","form_type":"8-K","filed_at":"2025-06-03T23:59:59+00:00","items":["8.01","3.01"],"status":"ready","headline":"Silexion Therapeutics appeals Nasdaq delisting; hearing set for June 26, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq delisting notice on May 22 for MVLS <$50M and MVPHS <$15M deficiencies.","Requested hearing on May 28, 2025, staying delisting; hearing scheduled June 26, 2025.","Intends to apply to transfer listing to Nasdaq Capital Market under Equity Standard requiring ≥$2.5M shareholders' equity.","No assurance of success; securities continue trading on Nasdaq under SLXN and SLXNW."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1744277.6056370838,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163716,"accession_number":"0001178913-25-002008","cik":2022416,"company_name":"Silexion Therapeutics Corp","ticker":"SLXN","form_type":"8-K","filed_at":"2025-05-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Silexion SIL204 shows ~90% inhibition in colorectal cells; expands to lung & pancreatic","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SIL204 inhibited GP2D colorectal cancer cells with ~90% inhibition rate in preclinical study.","Dose-dependent reduction observed in Panc-1 (pancreatic), A427 (lung) cell lines at nanomolar concentrations.","Company to conduct additional lung (NSCLC) cancer cell line study in coming weeks.","KRAS G12D mutation targeted; addresses pancreatic (~90%), colorectal (~45%), and lung (~35%) cancers.","Ilan Hadar cites SIL204's enhanced lipid-conjugate delivery enabling potent activity at low doses."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1744277.6056370838,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163715,"accession_number":"0001178913-25-001941","cik":2022416,"company_name":"Silexion Therapeutics Corp","ticker":"SLXN","form_type":"8-K","filed_at":"2025-05-23T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Silexion Therapeutics receives Nasdaq delisting notice; plans appeal","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received delisting notice on May 22, 2025 for MVLS <$50M and MVPHS <$15M non-compliance.","Failed to regain compliance within 180-day period ending May 19, 2025.","Intends to appeal by May 29, 2025; trading suspension effective June 2, 2025 if appeal fails.","Plans to request transfer to Nasdaq Capital Market; requires at least $2.5M shareholders' equity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1744277.6056370838,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2025-05-23T23:59:59+00:00|163715"}